A Phase 1 Safety and Tolerability Study of ZEN003694 in Patients With Metastatic Castration-Resistant Prostate Cancer
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 16 Aug 2017
At a glance
- Drugs ZEN 3694 (Primary)
- Indications Prostate cancer
- Focus Adverse reactions
- Sponsors Zenith Epigenetics Corp
- 10 Aug 2017 Status changed from recruiting to active, no longer recruiting.
- 10 Jun 2017 Biomarkers information updated
- 12 Apr 2016 Status changed from not yet recruiting to recruiting.